Amwell® Announces Results for First Quarter 2026
Rhea-AI Summary
Amwell (NYSE: AMWL) announced financial results for the first quarter ended March 31, 2026, and will host a conference call today at 5:00 p.m. ET. The earnings report and a live audio webcast are available at the company's investor site; a replay will be available for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – AMWL
On the day this news was published, AMWL gained 12.42%, reflecting a significant positive market reaction. Argus tracked a peak move of +15.9% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $128.66M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, AMWL showed a 4.9% gain versus mixed peers: HCAT up 6.08%, while CCLD, SOPH, and MNDR were down and FORA was flat. Momentum scanner only flagged BEAT moving up, with no cluster of peers in the same direction, pointing to stock-specific dynamics rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Q4/FY25 earnings | Neutral | +24.7% | Reported Q4 and full-year 2025 results with 5 p.m. ET conference call. |
| Nov 04 | Q3 2025 earnings | Neutral | -9.5% | Announced Q3 2025 results and scheduled same-day 5 p.m. ET call. |
| Aug 05 | Q2 2025 earnings | Neutral | -7.3% | Released Q2 2025 results with investor webcast and 90-day replay. |
| May 01 | Q1 2025 earnings | Neutral | +19.7% | Announced Q1 2025 results and hosted 5 p.m. ET conference call. |
| Feb 12 | Q4/FY24 earnings | Neutral | -5.0% | Reported Q4 and full-year 2024 results with webcasted investor call. |
Earnings releases have produced mixed reactions, with both strong rallies and notable selloffs around prior quarterly results.
Over the past year, Amwell has followed a consistent pattern of announcing quarterly and annual results with an associated 5 p.m. ET conference call and ~90-day webcast replay. Prior earnings-related moves ranged from a +24.71% jump after Q4/FY 2025 results on Feb 12, 2026 to declines of -9.5% and -7.31% after Q3 and Q2 2025 results. The current Q1 2026 announcement fits this cadence of regular financial disclosures and post-close calls.
Historical Comparison
In the past five earnings releases, AMWL’s average move was 4.52%, with both sharp gains and pullbacks. Today’s earnings-related move around +4.9% sits close to this typical post-earnings magnitude.
The company has maintained a steady cadence of quarterly and annual earnings releases from Q1 2024 through FY 2025, each paired with a 5 p.m. ET call and webcast replay.
Market Pulse Summary
The stock surged +12.4% in the session following this news. A strong positive reaction aligns with Amwell’s history of sizable earnings-related moves, such as prior swings of +24.71% and +19.71%. However, reactions have also been negative after some quarters, showing that sentiment can reverse quickly once investors digest details. Investors typically watch revenue mix, margins, and cash flow trends in the posted Q1 2026 materials for durability of any upside.
Key Terms
saas-based technical
AI-generated analysis. Not financial advice.
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the first quarter ended March 31, 2026. The company’s first quarter earnings report can be viewed at investors.amwell.com.
Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/b826q95x/. A webcast replay will be available for approximately 90 days at investors.amwell.com.
About Amwell
Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.
Contacts
Media:
press@amwell.com
Investors:
Asher Dewhurst
amwell@icrhealthcare.com
